You are here

Recent Pfizer Press Releases

3/9/16 6:45am EST
Pfizer Commences $5 Billion Accelerated Share Repurchase

Accelerated Share Repurchase Assumed in Pfizer’s 2016 Financial Guidance Issued on February 2, 2016

Pfizer Inc. (NYSE:PFE) today announced that it has entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS&Co.) to repurchase $5 billion of Pfizer’s common stock. This agreement is part of Pfizer’s existing share repurchase authorization.

more...
3/8/16 5:00pm EST
Pfizer Announces Publication of Study Results of BeneFIX® Coagulation Factor IX (Recombinant) Once-Weekly Prophylaxis for Hemophilia B

Phase 3 Study showed Prophylaxis With BeneFIX Significantly Reduced Annualized Bleeding Rate Compared to On-Demand Therapy

Pfizer Inc.

more...
3/8/16 1:31pm EST
Pfizer Consumer Healthcare and frog Launch Design Collaborative

New initiative and co-working approach will accelerate innovative solution development to improve health and wellness

frog, the global design and strategy firm, and Pfizer Consumer Healthcare (PCH) today announced the launch of the Design Collaborative, an ongoing initiative that will develop new health and wellness solutions for consumers in the areas of improved sleep, stress management, energy, aging and nutrition. 

more...
2/24/16 11:15am EST
2/19/16 4:35pm EST
Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer

  • First-in-class Therapy Now Approved for Use in a Broader Range of Women
  • New Indication Supported by Results of Phase 3 PALOMA-3 Trial of IBRANCE in Combination with Fulvestrant

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE® (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy.

more...
2/16/16 6:45am EST
WYETH REACHES AGREEMENT IN PRINCIPLE TO RESOLVE MEDICAID DRUG REBATE CLAIMS FOR 2001-2006 PERIOD FOR PROTONIX

Please find Pfizer’s press release and accompanying unaudited Consolidated Statements of Operations and notes thereto at the following hyperlink: 
more...
2/9/16 6:57pm EST
Pfizer Commends The FDA Advisory Committee’s Vote To Approve Proposed Biosimilar Infliximab, The First Biosimilar Monoclonal Antibody Reviewed, For All Eligible Indications

Pfizer Inc. commends today’s recommendation by the United States (U.S.) Food and Drug Administration’s (FDA) Arthritis Advisory Committee to approve the investigational biosimilar infliximab (CT-P13) across all eligible indications by a vote of 21 to three. Celltrion's proposed biosimilar infliximab, to which Pfizer holds exclusive U.S.

more...
2/8/16 9:30am EST
Pfizer Names Executive Leadership Team for Combined Organization Upon Close of Proposed Allergan Transaction

Pfizer will continue to manage its commercial operations through two distinct businesses – the innovative products business and the established products business – after the completion of the proposed transaction
 
Pfizer continues to expect to make a decision about a potential separation of the combined company’s innovative and established businesses by no later than the end of 2018

Pfizer Inc. (NYSE: PFE) today announced the executive leadership team for the combined Pfizer and Allergan plc (NYSE: AGN) business following the close of the proposed transaction.

more...
2/2/16 6:45am EST
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2015 RESULTS PROVIDES 2016 FINANCIAL GUIDANCE

 

 

 

Please find Pfizer’s press release and associated financial tables, including reconciliations of certain GAAP reported to non-GAAP adjusted information, at the following hyperlink:
more...
1/8/16 4:13pm EST
Pfizer Expands R&D Equity Investment Strategy to Access Early-Stage Scientific Innovations

Initial Investments in Companies Focused on Conditionally Active Biologics, Immuno-Oncology, Neurodegenerative Technologies and Gene Therapy Provide Access to Pfizer Resources to Help Accelerate Research into Novel Pathways and Technologies

Pfizer Inc. (NYSE:PFE) today announced an expansion of its Research & Development (R&D) investment strategy to include early-stage companies on the leading edge of scientific innovation, providing them with both equity and access to resources for research in promising areas aligned with Pfizer’s core interests.

more...
1/8/16 8:00am EST
Pfizer Enters into Translational Research Collaboration with Adaptive Biotechnologies to Help Advance Novel Immuno-Oncology Solutions

Pfizer Inc. (NYSE: PFE) and Adaptive Biotechnologies Corporation have entered into a translational research collaboration to leverage next generation sequencing of the adaptive immune system to advance Pfizer’s growing immuno-oncology franchise.

more...
1/4/16 8:00am EST
Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer

  • Merck KGaA, Darmstadt, Germany, Pfizer and Syndax will collaborate to investigate safety, tolerability and preliminary efficacy of avelumab and entinostat in advanced ovarian cancer

Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Pharmaceuticals, Inc.

more...

Pages